Answers are grounded in this paper and cite their sources.
Case report observes prostate cancer in a patient with Muir-Torre syndrome, suggesting diagnostic challenges in rare cases.
Muir-Torre syndrome (MTs) is a rare autosomal dominant disorder characterized by sebaceous neoplasms and internal malignancies, most commonly colorectal and urothelial cancers. Prostate cancer is exceptionally rare in MTs, with only thirteen cases reported to date. We present the case of a 65-year-old male initially diagnosed with MTs following the development of multiple sebaceous tumors and identification of a heterozygous MSH6 mutation. Immunohistochemistry demonstrated isolated loss of MSH6 protein expression, with preserved microsatellite stability—an unusual finding in MTs. Despite two negative prostate biopsies and a transurethral resection, choline PET imaging revealed hypermetabolic pelvic and cervical lymph nodes. Excisional biopsy confirmed metastatic prostate adenocarcinoma (NKX3.1-positive). The patient received first-line androgen deprivation therapy with an LH-RH analogue and apalutamide, achieving a sustained biochemical response. He remained alive and on treatment with undetectable PSA three years later, at the age of 74. This case highlights the diagnostic challenges of prostate cancer in MTs and the need to consider metastatic disease in atypical presentations, especially when MMR deficiency is suspected.
No takes yet. Share an insight, caveat, or question.
Crety et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: